This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IK-1001

Mallinckrodt plc

Drug Names(s): sodium sulfide

Description: IK-1001 is hydrogen sulfide administered intravenously as sodium sulfide.

Hydrogen sulfide has been shown to exhibit potent vasodilator activity both in vitro and in vivo most probably by opening vascular smooth muscle Potassium (ATP) channels. Hydrogen sulfide may also have the potential to modulate metabolism to a state in which cells need less energy and oxygen. This may help lengthen the period of time that tissues and cells can survive without oxygen in various forms of critical illness.

Deal Structure: Mallinckrodt and Ikaria
In March 2015, Mallinckrodt announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria in a transaction valued at approximately $2.3 billion.

In April 2015, Mallinckrodt completed its acquisition of Ikaria at a purchase price of approximately $2.3 billion. The all-cash transaction is expected to add at least $150 million in net sales and be accretive to the company's fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.


IK-1001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug